NCT02891798

Brief Summary

After total joint replacement, early hospital discharge to home (with patients capable of continuing a home-based rehabilitation program) is a cost- effective management strategy. This project will use improved local anesthetic nerve block techniques to enhance technical capability and clinical practice by (i) reducing pain and other morbidities during recovery, (ii) improving weight-bearing achievement during in-hospital physical therapy to allow for earlier return home, and (iii) continued rehabilitation as an outpatient at home when feasible (versus in an extended care facility).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P25-P50 for phase_3 pain

Timeline
Completed

Started Oct 2016

Longer than P75 for phase_3 pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 12, 2016

Completed
27 days until next milestone

First Posted

Study publicly available on registry

September 8, 2016

Completed
23 days until next milestone

Study Start

First participant enrolled

October 1, 2016

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 12, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 20, 2021

Completed
4 months until next milestone

Results Posted

Study results publicly available

December 20, 2021

Completed
Last Updated

January 14, 2022

Status Verified

January 1, 2022

Enrollment Period

4.8 years

First QC Date

August 12, 2016

Results QC Date

October 13, 2021

Last Update Submit

January 5, 2022

Conditions

Keywords

analgesia,buprenorphineclonidinedexamethasonebupivacainenerve block

Outcome Measures

Primary Outcomes (3)

  • Short-Form McGill Pain Questionnaire (Version 2) Total Score Difference From Baseline

    SF-MPQ version 2 total score difference of Post-Operative Day 1 value minus the Baseline value. Differences can range from -10 to +10. Negative scores indicate a decrease in pain.

    Baseline, Post-Operative day after surgery (7AM-9AM EST)

  • SF-MPQ2 Continuous Pain Subscore Difference From Baseline

    Continuous pain subscore difference of Post-Operative Day 1 value minus the Baseline value. Differences can range from -10 to +10. Negative scores indicate a decrease in pain.

    Baseline, Post-Operative day after surgery (7AM-9AM EST)

  • SF-MPQ2 Intermittent Pain Subscore Difference From Baseline

    Intermittent pain subscore difference of Post-Operative Day 1 value minus the Baseline value. Differences can range from -10 to +10. Negative scores indicate a decrease in pain.

    Baseline, Post-Operative day after surgery (7AM-9AM EST)

Secondary Outcomes (5)

  • Quality of Recovery 15 Item Scale (QoR-15) Total Score

    Day after surgery (7AM-9AM EST)

  • Quality of Recovery 15 Item Scale (QoR-15) Total Score

    6 weeks post-operation

  • Performed-based Physical Function is Assessed Using the Standing Balance Test.

    6 weeks post-operation

  • Performed-based Physical Function is Assessed Using the Self-Selected Gait Speed Test.

    6 weeks post-operation

  • Performed-based Physical Function is Assessed Using the Repeated Chair Stand Test.

    6 weeks post-operation

Study Arms (2)

Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)

EXPERIMENTAL

Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)

Drug: Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)

Bupivacaine Only (control arm)

ACTIVE COMPARATOR

Patients will receive a nerve block consisting of bupivacaine only.

Drug: Bupivacaine Only (control arm)

Interventions

Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements

Also known as: "Marcaine" + CBD (clonidine, buprenorphine, dexamethasone)
Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)

Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements

Also known as: Marcaine
Bupivacaine Only (control arm)

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 85, and undergoing a total knee or hip replacement.
  • Fluent in English, decision competent, willing and able to provide written informed consent, and able to complete the study's schedule of assessments.
  • Able to walk \>3m without an assisting device.
  • Have a BMI ≤ 40 kg/m2.

You may not qualify if:

  • Current participation in another orthopedic/Physical Therapy/rehab/anesthesiology interventional clinical trial.
  • Are at significant behavioral risks or have refractory major psychiatric disorders.
  • Revision surgery on the same extremity.
  • Have an American Surgical Association (ASA) Physical Status classification of 4 or higher.
  • Have been diagnosed with clinically significant neuropathy with its origins in either diabetes or other causes; have neuromuscular disease that would influence data collection.
  • Have a surgically-fused lumbar spine, or a spinal cord simulator, or other condition that would contraindicate or prohibit the conduct of spinal anesthesia.
  • Are undergoing Total Knee Arthroplasty (TKA)/Total Hip Arthroplasty (THA) for a tumor.
  • Have contraindications (e.g., anaphylaxis) to any of the study drugs.
  • Have a systemic fungal infection.
  • Have a known hypersensitivity to bupivacaine hydrochloride or to any local anesthetic of the amide-type or to other components of bupivacaine hydrochloride solutions.
  • Have a known or suspected buprenorphine hypersensitivity (not including nausea and/or vomiting).
  • Have a gastro-intestinal (GI) obstruction.
  • Have paralytic ileus.
  • Pregnant women
  • Have had a kidney or liver transplant.
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA Pittsburgh Healthcare System

Pittsburgh, Pennsylvania, 15240, United States

Location

Related Publications (2)

  • Aloziem OU, Williams BA, Mikolic JM, Boudreaux-Kelly MY, Faruque S, Piva SR, Ibinson JW, Switzer GE. Assessing Common Content and Responsiveness of the QoR-15 and the SF-8 in the Context of Recovery from Regional Anesthesia for Joint Replacement. Mil Med. 2023 Nov 3;188(11-12):e3469-e3476. doi: 10.1093/milmed/usad191.

  • Williams BA, Ibinson JW, Mikolic JM, Boudreaux-Kelly MY, Paiste HJ, Gilbert KL, Bonant SA, Ritter ME, Ezaru CS, Muluk VS, Piva SR. Day-One Pain Reductions After Hip and Knee Replacement When Buprenorphine-Clonidine-Dexamethasone Is Added to Bupivacaine Nerve/Plexus Blocks: A Randomized Clinical Trial. Pain Med. 2022 Jan 3;23(1):57-66. doi: 10.1093/pm/pnab325.

MeSH Terms

Conditions

PainAgnosia

Interventions

BupivacaineClonidineBuprenorphineDexamethasone

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesImidazolinesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMorphinansOpiate AlkaloidsAlkaloidsHeterocyclic Compounds, Bridged-RingHeterocyclic Compounds, 4 or More RingsHeterocyclic Compounds, Fused-RingPhenanthrenesPolycyclic Aromatic HydrocarbonsPolycyclic CompoundsPregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsSteroids, Fluorinated

Limitations and Caveats

The sample size determined before the study began was N=100 patients to undergo primary THA and N=100 patients to undergo primary TKA, with these patients not undergoing physical therapy until day-one after surgery; these sample sizes were ultimately not achieved. By early 2018, same-day physical therapy (after surgery) became the new hospital guideline for patients undergoing primary THA and TKA, such that by mid-2018, the study was interrupted. Only the described 78 patients completed.

Results Point of Contact

Title
Brian A. Williams, MD, MBA
Organization
VA Pittsburgh Health System, and University of Pittsburgh

Study Officials

  • Brian Williams, MD, MBA

    VA Pittsburgh Healthcare System

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR INVESTIGATOR
PI Title
VAPHS Surgical Specialties Service Line Medical Director

Study Record Dates

First Submitted

August 12, 2016

First Posted

September 8, 2016

Study Start

October 1, 2016

Primary Completion

July 12, 2021

Study Completion

August 20, 2021

Last Updated

January 14, 2022

Results First Posted

December 20, 2021

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will not share

Locations